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Abstract
Background: Depression, cardiovascular disease (CVD) risk factors and cognitive impairment are important causes
of disability and poor health outcomes. In combination they lead to an even worse prognosis. Internet or web-
based interventions have been shown to deliver efficacious psychological intervention programs for depression on
a large scale, yet no published studies have evaluated their impact among patients with co-existing physical
conditions. The aims of this randomised controlled trial are to determine the effects of an evidence-based internet
intervention program for depression on depressive mood symptoms, cognitive function and treatment adherence
in patients at risk of CVD.
Methods/Design: This study is an internet-based, double-blind, parallel group randomised controlled trial. The trial
will compare the effectiveness of online cognitive behavioural therapy with an online attention control placebo.
The trial will consist of a 12-week intervention phase with a 40-week follow-up. It will be conducted in urban and
rural New South Wales, Australia and will recruit a community-based sample of adults aged 45 to 75 years.
Recruitment, intervention, cognitive testing and follow-up data collection will all be internet-based and automated.
The primary outcome is a change in severity of depressive symptoms from baseline to three-months. Secondary
outcomes are changes in cognitive function and adherence to treatment for CVD from baseline to three, six and
12-months.
Discussion: Prior studies of depression amongst patients with CVD have targeted those with previous vascular
events and major depression. The potential for intervening earlier in these disease states appears to have
significant potential and has yet to be tested. Scalable psychological programs using web-based interventions
could deliver care to large numbers in a cost effective way if efficacy were proved. This study will determine the
effects of a web-based intervention on depressive symptoms and adherence to treatment among patients at risk
of CVD. In addition it will also precisely and reliably define the effects of the intervention upon aspects of cognitive
function that are likely to be affected early in at risk individuals, using sensitive and responsive measures.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR): ACTRN12610000085077
Background
Ischaemic heart disease and major depression are the
two leading causes of disease burden as measured using
disability-adjusted life years in OECD countries,
contributing 9.0% and 6.8% of the total burden respec-
tively. The associated conditions of stroke, diabetes and
alcohol abuse are also among the top ten causes of dis-
ease burden [1]. Dementia contributes a further 2.9%
and is increasing in the ageing Australian population.
T h eW o r l dM e n t a lH e a l t hs t u d yd e m o n s t r a t e dt h a t
the individual health decrement (disability) arising from
depression-physical disorder co-morbidity produces
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additive effects [2]. Furthermore, treatments are typically
targeted only at those with major depressive disorder
although the public health impact of lesser symptom
severity is highly significant [3,4]. The large numbers with
sub-clinical or ‘subsyndromal’ disease contribute a greater
disease burden than the few with severe illness [5]. Provid-
ing acceptable, non-toxic interventions on a large scale for
those with less severe depressive symptoms in the com-
munity is therefore a key public health goal.
The relationships between depression and cardiovas-
cular disease (CVD) are complex with bidirectional
pathways [6]. Depression has been shown to have a rela-
tively strong association with the development of fatal
coronary heart disease as well as myocardial infarction.
This finding has been demonstrated by a number of
longitudinal studies published over the last 40 years, is
particularly true in men [7] and is apparent across the
range of depression symptom severity [7].
Although depression is consistently associated in
observational studies with poor outcome in people with
both established CVD and with risk factors for CVD [7],
all major randomised controlled trials (RCTs) have eval-
uated the effect of treating depression only in those with
an established event such as myocardial infarction.
These trials aiming to treat depression and thus reduce
CVD have produced mixed results. Despite demonstrat-
i n gr e a s o n a b l ee v i d e n c ef o ran antidepressant response
in a number of studies [8-10], no benefits were found in
prevention of recurrent events or cardiac death. This
was also true of the most recently reported trial (CRE-
ATE; [11]). There remains, however, the possibility that
intervention in people with less severe disease (i.e.,
either less severe depressive symptoms or cardiovascular
risk factors) might be of benefit [12]. For example, peo-
ple at high risk for CVD (e.g. raised cholesterol, smo-
kers) but without established disease may have
suboptimal medical management, in addition to psycho-
social factors, which may play a greater role in factors
such as adherence. We propose that new interventions
need to target these ‘at risk’ individuals.
Poor adherence to medications is an issue that is often
linked with depression in conceptual papers but rarely
addressed in clinical studies. Adherence describes a per-
son’s implementation of a health related behavioural pre-
scription, such as correctly taking a medication, or
exercising according to an agreed plan. Depression is one
the most consistent determinants of poor adherence to
physical treatments [13] and medication [14]. Poor adher-
ence is often postulated to mediate the effects of depres-
sion on cardiovascular outcomes. To date, however, there
has been no RCT evaluating whether an intervention
designed to improve depression in those with co-morbid
CVD also improves adherence to preventative therapies.
In addition to the range of poor physical health out-
comes, depression is also associated with impaired cog-
nition. Typically, dysfunction is evident in those regions
mediated by fronto-subcortical brain circuitry, with
impairments being most pronounced in processing
speed, executive functioning and memory [15]. These
impairments are predictive of disability and poor quality
of life [16] and often persist despite symptom resolution
[17]. While the precise mechanisms are unknown, cog-
nitive impairment in older people with depressive symp-
toms may be due to a combination of underlying
cerebrovascular disease, as well as the direct neurotoxic
effects of depression itself. This research underscores
the need to deliver targeted interventions for these mod-
ifiable risk factors as early as mid-life [18]. To-date, no
known trials have evaluated the effect of treating depres-
sive symptoms upon the subtle early cognitive impair-
ments observed in this ‘at risk’ group.
Taken together, the literature on depression and CVD
would suggest that there exists a group of individuals
with both higher cardiovascular risk and depressive
symptoms whose coexistence can initiate a negative
spiral towards worse CVD and mental health outcomes.
Taken in turn, this is likely to have deleterious effects on
cognitive functioning, and levels of disability. Given the
rapidly, ageing population, there is a need to address
these issues on a large-scale at primary and secondary
levels of prevention. Internet or web-based interventions
(e-health) may be ideally suited for this purpose since
they have been shown to deliver efficacious psychological
intervention programs for depression [19] on a large
scale in a cost effective manner. Moreover, there is evi-
dence that internet interventions are preferentially sought
for their anonymity, their capacity to be used privately at
home and for their lack of face-to-face contact. As such
they may increase participation among individuals who
might not otherwise seek care [20]. Middle-aged men, a
key target group for early cognitive decline, are particu-
larly hard to engage in standard health care. Internet
interventions - if automated - are able to deliver interven-
tions with fidelity, giving them an advantage over other
types of programs. In younger samples, data suggests that
internet interventions are effective for a range of mental
health symptoms including depression, post traumatic
stress disorder, and eating disorders [21] and some stu-
dies have shown sustainable benefits [22]. To-date, there
have been no published evaluations of web-based treat-
ments for mood and co-morbid physical disorders in
older people, although trials in younger samples appear
to be underway [23].
The primary aim of the Cardiovascular Risk, E-couch
Depression Outcome (CREDO) research trial is to deter-
mine the efficacy of an internet intervention program
for depression (e-couch)o nd e p r e s s i v es y m p t o m si n
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The secondary aims are to determine the immediate, six
and 12-month efficacy of the same intervention on cog-
nitive function and adherence to treatment for CVD.
Methods/Design
Study Design
This study is a randomised, double-blind, controlled trial
of parallel design. Participants will be randomly allocated
to one of two groups: e-couch, an online program that
primarily provides cognitive behavioural therapy (CBT)
yet also incorporates modules on interpersonal psy-
chotherapy (IPT), relaxation and physical activity; and
HealthWatch, an online active control program. The trial
consists of a 12-week intervention treatment phase with
a 40-week follow-up phase. The total trial period will be
12-months. As shown in Figure 1, measurements will be
undertaken at four time-points in each group: at baseline,
directly after completing the 12-week internet program,
and at six and 12-month follow-up.
Participants and Setting
Sample
The target population for the trial are older adults, both
male and female aged 45 to 75 years, with self-reported
CVD history or significant risk factors, and evidence of
depressive symptoms.
Participants will be recruited through the 45 and Up
Study, a large-scale longitudinal population-based cohort
study comprising over 260,000 men and women aged
45 years and over in New South Wales (NSW), Australia
[24]. Participants in the 45 and Up Study were ran-
domly selected from the database that is used to admin-
ister the national universal health insurance scheme
(Medicare Australia), which has almost complete cover-
age of the Australian population. Participants entered
the study by completing a baseline postal questionnaire
and providing written consent to have their health fol-
lowed over time. The study questionnaire is available at
http://www.45andUp.org.au The overall response rate to
the baseline questionnaire is 18%. Comparative analysis
between the 45 and Up Study and the NSW Population
Health Survey demonstrates that for a range of risk fac-
tors the estimates of relative risk observed in the 45 and
Up Study are generalisable to the wider population [25].
Recruitment
Potential participants will be randomly selected from the
45 and Up Study database using an algorithm to identify
those that meet the eligibility criteria and have provided
a valid email address. The individuals identified will be
contacted via email, given brief information about the
trial and provided with a Trial ID and a link to the trial
website. Interested participants will log into the website
using their Trial ID where they will be provided with
more detailed information and undertake an online con-
sent, eligibility screening and baseline assessment proce-
dure. Recruitment will be conducted in waves of
approximately 1,000 until the desired sample size is
reached.
Eligibility Criteria
Inclusion criteria: To be eligible to be screened for parti-
cipation in the trial, individuals must have an email
address and have satisfied the following two criteria in
the 45 and Up Study baseline questionnaire:
1. Self-reported history of CVD, or risk factors for
CVD, defined as any one of the following:
- Receiving treatment for heart attack/angina, other
heart disease, hypertension or high blood cholesterol
in the past month;
- Taking the following medications listed in the 45
and Up Study questionnaire for heart disease, hyper-
tension or high blood cholesterol in the past month:
L i p i t o r ,P r a v a c h o l ,a s p i r i nf o rt h eh e a r t ,A v a p r o ,
Karvea, Coversyl, Coversyl Plus, Cardizem, Vasocardol,
Norvasc, Tritace, Noten, Tenormin, atenolol, warfarin,
Coumadin, Lasix, frusemide, and Micardis;
- Previous doctor’s diagnosis of heart disease, stroke
or hypertension;
- Previous doctor’s diagnosis of diabetes and report
taking glucose lowering therapy in the past month;
- Two or more of the following risk factors: current
smoker, obese, aged 65 years or more, family history
of heart disease or stroke in two or more first degree
relatives.
2. Self-reported psychological distress defined as a
Kessler-10 (K-10) score of greater than or equal to 16.
In addition, at the time of eligibility screening, indivi-
duals must have a score of 8 or above on the Patient
Health Questionnaire (PHQ-9), thus demonstrating the
presence of clinically significant depressive symptoms at
the point of entry to the trial.
Exclusion criteria: Those excluded will be individuals
with either no depressive symptoms, or those that
express suicidal ideation as determined from the PHQ-9.
Also, those individuals that report they are currently
receiving any form of counselling, e.g., with a counsellor,
general practitioner, psychiatrist or psychologist will be
excluded. Refer to Table 1.
Procedure
The Participant Information Statement and Consent
Form will be available on the trial website and available
for download. The Participant Information Statement
provides a detailed description of the trial, the proce-
dures and time involved in participating, information on
the randomisation process each participant will undergo
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dentiality information and contact information for the
trial team should potential participants want further
information.
In providing consent, within the online form partici-
pants will be required to: enter their full name; indicate
their agreement with two statements by checking a yes/
no response button and then; click on submit. The date
consent is submitted will be recorded.
Once online consent is obtained the potential parti-
cipant will complete the PHQ-9 and questions relating
to any form of counselling currently being received.
Participants deemed to be eligible and will be asked to
complete the baseline data collection which comprises
Allocated to Online Intervention 
Treatment: e-couch (n=320) 
Allocated to Online Attention 
Control: HealthWatch (n=320) 
t = 1 week 
Completion of program and online 
post-program assessment (n=?) 
Completion of program and online 
post-program assessment (n=?)  t = 13 weeks 
Completion of 6-month online 
follow-up assessment (n=?) 
Completion of 6-month online 
follow-up assessment (n=?) 
t = 24 weeks 
Completion of 12-month online 
follow-up assessment (n=?) 
Completion of 12-month online 
follow-up assessment (n=?) 
t = 48 weeks 
Loss to follow-up or discontinued (n=?) 
Confirm continued willingness to participate  
(t = 1 week)
Random selection from 45 and Up Study Cohort as per 
sampling frame (n=8,000) 
Potential participant visits trial website; trial 
information provided 
Online informed consent 
Assessment of eligibility based on online 
inclusion/exclusion questions (PHQ-9 and current 
psychotherapy) 
Complete baseline assessment and cognitive assessment 
(t = 0 weeks) 
Invitation to participate sent via Email 
Excluded: No 
informed consent
Excluded: No 
depressive symptoms; 
suicide ideation; 
receiving 
psychotherapy 
Excluded: Baseline 
assessment not 
completed within 2 
weeks
Excluded: No longer 
willing to be in trial 
Randomisation 
(t = 1 week)
Figure 1 Flow of Participants.
Cockayne et al. BMC Psychiatry 2011, 11:10
http://www.biomedcentral.com/1471-244X/11/10
Page 4 of 10as u r v e ya n dc o g n i t i v et e s tb a t t e r y ;CogState.P a r t i c i -
pants will be encouraged to complete both the baseline
survey and cognitive tests within one week. Within
one day of completing their baseline assessment, parti-
cipants will receive an automated email thanking them
for their involvement and confirming the next steps of
the trial. Ongoing participation in the trial will be
measured from this time-point. Refer to Figure 1.
Eligible participants that complete the baseline assess-
ment will be prompted with an automated email one
week later asking them to return to the trial website to
commence their internet program. Participants will be
required to login and confirm their continued willing-
ness to participate in the trial. The process of confirm-
ing their willingness to participate will automatically
trigger the randomisation facility built into the internet
program. Refer to Figure 1.
Randomisation
Randomisation will be undertaken using a customised
and fully automated randomisation facility built into the
trial website. Participants will be randomised to receive
either the intervention program (e-couch) or the active
control program (HealthWatch). Randomisation will be
stratified by depressive symptom severity using specified
block sizes of eight. Symptom severity will be deter-
mined using PHQ-9 scores, where scores ranging from
8 to 14 are classified as moderate depressive symptoms,
and scores ranging from 15 to 27 are classified as major
depressive symptoms. The computerised procedure
allows for full replication.
Interventions
Active Treatment Arm: e-couch
E-couch is an automated software program that offers 12
modules addressing mental health literacy (information
about the nature, risk factors and effective treatments
for depression), CBT, IPT, relaxation techniques and
exercise programs targeting depression. The CBT and
mental health literacy components of e-couch are exten-
sions of the MoodGYM [26] and BluePages [27] internet
interventions, which have efficacy demonstrated in pre-
vious trials [28]. Both of these programs have been
found to reduce depression symptoms in community
samples relative to placebo conditions [19,29].
Active Control: HealthWatch
HealthWatch is a 12-week program in which participants
read information about environmental health, nutrition,
stroke, physical activity, medicines in the home, tempera-
ture extremes, oral health, blood pressure and cholesterol,
heart health, bacteria and food-borne illnesses, calcium
and back pain. In order to replicate the interactive compo-
nent of the active treatment arm, participants also com-
plete online questionnaires that probe health factors,
physical and artistic activities, education and hobbies,
social, financial, and family roles, work habits and stress,
medications, pain and nutrition, and alcohol use.
Intervention Procedure
Modules are made available sequentially weekly and take
between 30 and 60 minutes to complete. An automated
Table 1 Inclusion/Exclusion Criteria
Inclusion Criteria
Self-reported history of any one of
the following CVD or risk factors in
the 45 and Up Study baseline
dataset
Report of treatment in the last
month for:
￿ Heart attack/angina
￿ Other heart disease
￿ High blood pressure
￿ High blood cholesterol
Report of taking any of the
following in past four weeks:
￿ Lipitor
￿ Pravachol
￿ Aspirin for the heart
￿ Avapro/Karvea
￿ Coversyl/Coversyl Plus
￿ Cardizem/Vasocardol
￿ Norvasc
￿ Tritace
￿ Noten
￿ Tenormin/atenolol
￿ Warfarin/Coumadin
￿ Lasix/frusemide
￿ Micardis
Previous doctor’s diagnosis of heart
disease or stroke or high blood
pressure
Previous diagnosis of diabetes and
taking at least one prescription of
glucose lowering therapy in the
last four weeks
Two or more of the following risk
factors:
￿ Regular smoker now
￿ Obese (Body Mass Index ≥ 30)
￿ Over 65 years
￿ Family history of heart disease or
stroke in two or more first degree
relatives
Self-reported psychological distress
in the 45 and Up Study baseline
dataset
A Kessler-10 (K-10) score of greater
than or equal to 16.
Depressive symptoms indicated at
pre-trial screening
A score of eight or above on the
27 point Patient Health
Questionnaire (PHQ-9)
Exclusion Criteria
No depressive symptoms at pre-
trial screening
A score less than or equal to seven
on the 27 point scale of the PHQ-9
Suicide ideation at pre-trial
screening
A score of either ‘2’ or ‘3’ on the 0-
3 likert scale at question nine of
the PHQ-9
Currently receiving psychotherapy
at pre-trial screening
Indication that currently receiving
any form of counselling e.g. with a
counsellor, GP, psychiatrist or
psychologist
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participants that their weekly module is available for
completion. A link on the email provides support for
technological problems. In each program, one new web-
site module will open each week regardless of whether a
participant has completed the previous one. For exam-
ple, at Week three, module three will be released. If a
participant has only completed module one, but logs on
in Week three they will be directed to complete Week
t w of i r s t .H o w e v e r ,t h e yw i l ln o th a v et ow a i taw e e k
between each of these modules since Week three will
have already been released. Each module will remain
open after it has been completed so that participants
may go back and revise any information.
If a participant has not logged in to the website and
completed the current module within four days of its
release, an automated reminder email will be sent. A
phone call will then be made three to four days after
the reminder email has been sent if they have still not
yet completed the new module.
Participant Monitoring and Follow-up Assessments
Participants will be monitored as the trial progresses
with questions relating to mood embedded within the
respective internet programs in Week four and Week
eight. Module completion will be monitored each week,
with automated reminder emails and follow-up phone
calls undertaken as outlined above.
Upon completion of the trial treatment program, par-
ticipants will be prompted by automated email to return
to the trial website to complete the post-program assess-
ment, comprising a survey and cognitive testing. Phone
calls will be made to participants that do not respond to
the automated email notification to encourage comple-
tion. Further follow-up assessments will be completed at
six and 12-months respectively following date of rando-
misation. Refer to Figure 1.
Data Collection
Reasons for exclusion and withdrawal or loss to follow-up
will be recorded. Table 2 provides an overview of the time-
frame for assessment and the measures that are used. Data
collection for the trial will be done online with questions
embedded in the trial website and in the respective inter-
vention programs or collected via the CogState (cognitive
testing) program. At six and 12-month follow-up, where a
participant no longer has access to the internet, the survey
component of the assessment will be conducted via phone
by blinded interviewers.
Outcome Assessment
Primary Outcome - Depressive Symptoms
The primary outcome for the trial is a change in severity
of depressive symptoms from baseline to three, six and
12-months. The primary outcome will be measured
using the PHQ-9; a nine-item assessment of depressive
symptoms, which provides a summary score ranging
from 0 to 27. The PHQ-9 is a reliable and valid measure
of depressive symptoms, which has been widely used in
previous studies of people with depressive symptoms
and is sensitive to change [30,31]. The PHQ-9 will be
embedded into the trial website and completed online at
baseline, post-program (three-months) and six and
12-month follow-up. Mean changes in continuous depres-
sive symptom scores from baseline will be compared
between the two randomised groups at each time-point.
Secondary Outcomes - Cognition and Adherence
Cognition: Cognitive function will be measured using
CogState, a computerised test battery with well estab-
lished validity and sensitivity to detect subtle cognitive
change in community cohorts [32-35]. For this trial, an
internet deliverable version will be utilised. The test bat-
tery was chosen for brevity as well as capacity to probe
psychomotor speed, memory and executive functioning.
Specifically the battery will take a maximum of 12-
minutes to complete and includes:
a) Psychomotor function/speed of processing: This
task requires participants to respond when a card
presented on-screen turns from face-down to face-
up (duration, two minutes) (outcome measure =
speed of performance, mean of the log10 transformed
reaction times for correct responses);
b) Visual learning and memory: In this task, playing
cards are presented on-screen and participants
respond ‘yes’ if the card has appeared in the task
before and ‘no’ if it has not (duration, up to five
minutes) (outcome measure = accuracy of perfor-
mance, arcsine proportion correct);
c) Executive functioning: In this spatial problem
solving task, participants are shown a grid of tiles
on-screen and using their mouse they must find a
hidden pathway on the basis of trial and error feed-
back (five minutes) (outcome measure = number of
errors).
The CogState test battery will be located on a dedi-
cated testing portal, linked to the trial website, with par-
ticipants instructed to complete the cognitive tasks as
part of the baseline, post-program (three-months), six
and 12-month follow-up assessment. Scores will be
compared between the two randomised groups at each
time-point.
Adherence: Adherence to CVD treatments will be
measured using the Medical Outcomes Study Measures
of Patient Adherence Scale. Comprising both general
and specific measures, this scale uses self report of
adherence to a number of dimensions. The general
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adhere to medical recommendations (scored as an
a v e r a g eo ft h ef i v ei t e m s ) ,w h i l et h es p e c i f i cm e a s u r e
(scored as a 0-100 scale) focuses on adherence to med-
ication, exercise, diet and social support (an important
additional factor in cardiovascular outcome post
event). It has been shown to be sensitive to changes in
mood [36]. Changes in mean general and specific
adherence behaviour scores will be calculated and
compared between the two randomised groups at each
time-point.
Other Outcomes
Other outcomes include: anxiety (using the Generalised
Anxiety Disorder Scale; GAD-7) [37], sleep quality
(using the Pittsburgh Sleep Quality Index; PSQI) [38],
disability (using the World Health Organisation Disabil-
ity Assessment Scale; WHODAS) [39], illness perception
(using the Brief Illness Perception Questionnaire; BIPQ)
[40], participation in physical activity (using the Active
Australia Baseline Survey; AABS) [41] and alcohol use
(using the Alcohol Use Disorders Identification Test -
Consumption; AUDIT-C) [42]. Medication use for CVD
and depression will also be determined, in addition to
workforce and social participation. Satisfaction with
treatment and reasons for drop-out will also be mea-
sured. Help-seeking using scales measuring actions to
overcome depression, preferences for treatment type
and expectations of the trial will be measured using
previously developed formats [29,43]. User behaviour
(e.g. time on site, number of modules completed, length
of individual module use and frequency of access) will
be tracked for both the e-couch and HealthWatch
programs. In addition, demographic and past medical
history data derived from the 45 and Up Study baseline
dataset will be available for analysis.
Refer to Table 2 for a list of all outcomes to be
assessed.
Blinding and allocation concealment
The investigators, analysts, trial manager and all partici-
pants will be blinded to treatment allocation for the
duration of the trial. Only the internet program system
administrator will have access to un-blinded data at the
individual level however they will not have any contact
with trial participants.
Treatment allocation will be preserved by virtue of the
intervention delivery method being web-based, in addi-
tion to all of the follow-up assessments. Where partici-
pants are unable to complete follow-up assessments
online, they will be conducted over the telephone by a
Research Assistant who will be blinded to allocation. In
the event that treatment allocation is revealed to the
Research Assistant duringt h es i x - m o n t hf o l l o w - u p
assessment, the subsequent 12-month follow-up assess-
ment will be conducted by a secondary Research Assis-
tant, who will also be blinded to allocation.
Table 2 Outcome Measures and Assessments
Baseline Assessment at
t = 0 months
Post-intervention Assessment at
t = 3 months
Follow-up Assessment at
t = 6 months
Final Assessment at
t = 12 months
Primary
Outcome:
PHQ-9 + + + +
Secondary
Outcomes:
CogState + + + +
MOS + + + +
Other
Outcomes:
PSQI + + + +
GAD-7 + + + +
WHODAS + + + +
AUDIT-C + + ... +
BIPQ + + ... +
AABS + + + +
Medication Use + + + +
Employment + + + +
Program
satisfaction
... + ... ...
Help-seeking ... + + +
Table legend text: PHQ-9 - Patient Health Questionnaire; CogState - series of cognitive tests; MOS - The Medical Outcomes Study Measures of Patient Adherence;
PSQI - Pittsburgh Sleep Quality Index; GAD-7 - Generalised Anxiety Disorder Scale; WHODAS - World Health Organisation Disability Assessment Scale; AUDIT-C -
Alcohol Use Disorders Identification Test; BIPQ - Brief Illness Perception Questionnaire; AABS - Active Australia Baseline Survey.
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Sample Size
We will randomly select 8,000 of those meeting trial elig-
ibility criteria from the 45 and Up Study to participate. A
conservative return rate of 20% is expected from this
invitation on the basis of results of previous population-
based internet trials [44]. Further assuming that only 40%
of those agreeing to potentially participate actually con-
sent after having responded or become un-contactable
over a one-month period or currently do not demon-
strate depressive symptoms or have access to counselling,
this leaves a potential sample of about 640. Taking into
account a 20% attrition rate post-randomisation, this will
provide a final sample of approximately 510.
Power Calculation
To detect an effect size of 0.3 standard deviations as the
difference between randomised groups in mean change
in depressive symptom scores at three-months, with a =
0.05 and b = 0.90, the required sample size for the trial
is 470.
Statistical Analyses
The primary a priori outcome is change in depressive
symptoms between baseline and three-months as mea-
sured by the PHQ-9 score. However, internet trials often
have missing data. Analyses of the change in this contin-
uous measure will be undertaken on an intention-to-treat
basis, including all participants randomised regardless of
treatment actually received or withdrawal from the study.
Mixed-model repeated measures (MMRM) analyses will
be used since this approach can include participants with
missing data and incorporate data from intermediate
measurement time points of four and eight weeks.
Mixed-models yield unbiased and efficient estimates
under MCAR (missing completely at random) and MAR
(missing at random) assumptions, which are often rea-
sonable in clinical trials. Additional analyses will explore
participant characteristics which moderate outcome and,
if appropriate, levels of presenting severity associated
with significant improvement. The latter analyses will use
a Johnson-Neyman approach [45].
A completers analysis on all participants completing at
least 75% of the internet modules and all measures will
be undertaken as a secondary analysis. Sensitivity ana-
lyses based on multiple imputation and on assuming all
drop outs are non-responders (worst case scenario) will
be undertaken.
The secondary outcomes of change in the continuous
measures of cognitive function and self-reported adher-
ence will be analysed in the same way.
Ethical Considerations
The trial will be undertaken in compliance with the
World Medical Association Declaration of Helsinki
(revised version of Seoul, 2008), international standards
of Good Clinical Practice (GCP) and the applicable reg-
ulatory requirements in Australia. The design and
implementation of the trial has been approved by The
University of Sydney Human Research Ethics Commit-
tee (Reference Number: 06-2009/11800).
T h et r i a li sb o u n db yC o m m o n w e a l t ha n dS t a t ep r i v -
acy legislation and guidelines within Australia, including
the Health Records and Information Privacy Act 2002.
All research data collected including survey responses,
cognitive testing results and website activity data will be
identified by the Trial ID numbers only. All files linking
participant names and contact information to Trial ID
numbers will be stored separately from raw research
data. All research data collected will be stored on a
secure server at the Brain & Mind Research Institute,
T h eU n i v e r s i t yo fS y d n e y .T h es e r v e rw i l lb ep a s s w o r d
protected and access permitted by authorised research
staff only.
A suicide/self-harm risk protocol is in place, which
includes a list of emergency sources of help. If partici-
pants wish to seek treatment elsewhere, they will be
advised to speak to their regular general practitioner or
will be provided with information to locate an appropri-
ate general practitioner in their local area. A referral list
of appropriate health professionals and services is in
place.
Discussion
This trial will bring together a multidisciplinary perspec-
tive from psychiatry, cardiology, psychology, neuropsy-
chology and neurology to study links between
depression, CVD and cognitive function using a novel
intervention. The trial will be one the first of its kind to
evaluate the efficacy of a web-based intervention for
depression in people aged 45 years and over with signifi-
cant depressive symptoms who are also being treated for
cardiovascular risk factors. In particular, this trial will
target people across the range of CVD, especially those
in early stage and those hard to access through usual
clinical channels.
The intervention itself (e-couch) is evidence-based
and can be rolled out in a high fidelity manner on a
large scale at low cost. It has the capacity to attract
those who don’t usually seek health care services and
to be delivered in areas with limited access, such as
rural and remote regions. Further, this will be the first
study to evaluate the effect of treating depression on
early cognitive impairment, using a novel internet
based assessment. The trial will also assess the effect
of intervening on people’s mood upon adherence to
treatment and lifestyle factors important in secondary
cardiovascular disease prevention. It will enable
exploration of mechanisms by which these may occur
in future studies.
Cockayne et al. BMC Psychiatry 2011, 11:10
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Page 8 of 10The study addresses an Australian national health
priority (ageing well, ageing productively). With health
reforms placing preventative services at the centre of
health efforts, such a scalable intervention may, if effica-
cious, have an important role in the amelioration of the
burgeoning impact of dementia.
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